Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 5/20 | 0.54 |
| ▸ | F13A1 | P00488 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TGM1 | P22735 | 1/20 | 0.54 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 5/20 | 0.47 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28220578 | 0.87 | EGFR (0.56) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL21894170 | 0.83 | TGM2 (0.58) | TGM2LMNAALDH1A1CYP2C19MAPK3 | |
| SCHEMBL22963894 | 0.83 | ALDH1A1 (0.39) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL31162390 | 0.83 | TGM2 (0.58) | TGM2LMNAALDH1A1CYP2C19MAPK3 | |
| SCHEMBL23293735 | 0.81 | TGM2 (0.47) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL11508898 | 0.81 | TGM2 (0.61) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL5234997 | 0.81 | MAPK1 (0.56) | LMNAKDM4EALDH1A1 | |
| SCHEMBL22749629 | 0.80 | ALDH1A1 (0.51) | LMNABTKKDM4EALDH1A1CYP2C19 | |
| SCHEMBL16104950 | 0.80 | TGM2 (0.46) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL16095513 | 0.80 | TGM2 (0.54) | TGM2F13A1LMNATGM1TGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110746424-A | MK2 inhibitors and uses thereof | 西建卡尔有限责任公司 | 2020-02-04 | — | — | CN | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| EP-2968339-A1 | MK2 INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | TGM2 1258/4885F13A1 4688/4885LMNA 4652/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | TGM2 1258/4885F13A1 4688/4885LMNA 4652/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | TGM2 1258/4885F13A1 4688/4885LMNA 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.